Noxopharm (NOX) Stock Price, News & Analysis

Company Overview

Noxopharm Limited, a biotech company, discovers and develops treatments for cancer and inflammation, and mRNA vaccines in Australia. It primarily develops Veyonda, a formulation of idronoxil for the treatment of solid tumors. The company also develops LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions; and Sofra platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases. The company was incorporated in 2015 and is based in Glenhaven, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 1.23 million shs
• Average Volume: N/A
• Market Capitalization: A$26.59 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NOX Stock Analysis - Frequently Asked Questions

How were Noxopharm's earnings last quarter?

Noxopharm Limited (ASX:NOX) announced its earnings results on Thursday, February, 21st. The company reported ($0.04) earnings per share (EPS) for the quarter. Noxopharm had a negative net margin of 149.07% and a negative trailing twelve-month return on equity of 59.29%.

What other stocks do shareholders of Noxopharm own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Noxopharm investors own include AMC Entertainment (AMC), Dimerix (DXB), Align Technology (ALGN), Aurora Cannabis (ACB), Bandwidth (BAND), Alteryx (AYX) and Axcella Health (AXLA).

Company Calendar

• Last Earnings: 2/21/2019
• Today: 7/14/2025

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:NOX
• CIK: N/A
• Web: www.noxopharm.com
• Phone: 61 2 9144 2223
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$3.58 million
• Net Margins: -149.07%
• Pretax Margin: N/A
• Return on Equity: -59.29%
• Return on Assets: -34.01%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.83
• Quick Ratio: 8.43

Sales & Book Value

• Annual Sales: A$2.40 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 15.42
• Book Value: A$0.02 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 292,240,000
• Free Float: N/A
• Market Cap: A$26.59 million
• Optionable: Not Optionable
• Beta: 0.78